A 72-year-old male underwent laparoscopic radical nephrectomy of left renal cell carcinoma in March 2010.
Pathological findings revealed clear cell renal cell carcinoma, G3, pT1b, INFα and v1. At 3 months after operation, computed tomography (CT) showed multiple metastases in bilateral lungs. Sunitinib was administered with a scheduled cycle of drug administration for 4 weeks at a dose of 37.5 mg/day followed by 2 weeks of rest. Administration of sunitinib was interrupted at day 18 due to common terminology criteria for adverse events v 3.0 (CTCAE) grade 2 thrombocytopenia. After 3 weeks, sunitinib was restarted with a scheduled cycle of drug administration for 2 weeks followed by 2 weeks of rest at the same dose. After 6 cycles, CT revealed complete response of lung metastasis and there was no evidence of the disease at 12- month follow-up.
Written by:
Kim H, Shoji S, Usui Y, Nagata Y, Terachi T, Uchida T. Are you the author?
The Department of Urology, Tokai University Hachioji Hospital.
Reference: Hinyokika Kiyo. 2013 Jan;59(1):7-10.
PubMed Abstract
PMID: 23412117
Article in Japanese.
UroToday.com Renal Cancer Section
